← All Achieve Life Sciences, INC filings

Achieve Life Sciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ACHV
Achieve Life Sciences, INC
10-K/A: Achieve Life Sciences Files 10-K/A for Governance Update
Achieve Life Sciences amends its 2025 Annual Report to include updated corporate governance, executive compensation, and director information.
NASDAQ
ACHV
Achieve Life Sciences, INC
10-K: Achieve Life Sciences Faces Delays, Going Concern Doubt
Achieve Life Sciences' 2025 annual report highlights significant operating losses, ongoing financing needs, and potential FDA approval delays for cytisinicline, despite positive clinical trial results and breakthrough therapy designation.
NASDAQ
ACHV
Achieve Life Sciences, INC
10-K: Achieve Life Sciences Reports 2024 Results, Highlights Cytisinicline Development
Achieve Life Sciences provides an update on its clinical development program for cytisinicline and reports its financial results for the year ended December 31, 2024.
NASDAQ
ACHV
Achieve Life Sciences, INC
10-K: Achieve Life Sciences Files 10-K, Provides Update on Cytisinicline Development
Achieve Life Sciences' 10-K filing details the company's financial status, clinical trial progress, and regulatory pathway for its lead product candidate, cytisinicline.